Navigation Links
Cannabinoid in Medical News

Turned-off cannabinoid receptor turns on colorectal tumor growth

HOUSTON - New preclinical research shows that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer, scientists report in the Aug. 1 edition of the journal Cancer Research . CB1 is well-established for relieving pain and nausea, elevating mood and stim...

Milestone for cannabinoid MS study

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study. CUPID is a clinical trial whi...

Synthetic Cannabinoid Could Improve Fertility in Smokers

A reproductive medicine expert from the University at Buffalo has demonstrated the capacity of a new compound that could enhance// the fertility of tobacco smokers, who have a deficient sperm count and sperm mobility. A synthetic chemical called AM-1346 was used to wash the sperm from male sm...

Pharmos Corporation Reports 2009 First Quarter Results

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Completes Private Placement - Raises $1.8 Million

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Marijuana use linked to increased risk of testicular cancer

... said. In future studies the researchers plan to measure the expression of cannabinoid receptors in both seminomatous and nonseminomatous tumor tissue from the ca...er variation in the genes for the receptors and other molecules involved in cannabinoid signaling influences the risk of testicular cancer. In the meantime, Schwa...

US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value

...t of the drugs recently approved in the world for the treatment of cancer pain are opiates. One exception is GW's dronabinol/cannabidiol (Sativex), a cannabinoid receptor agonist recently approved in Canada for the treatment of cancer pain. The US has not seen a recent approval, but BDSI's ONSOLIS has reached ...

Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana

...eneral Psychiatry , one of the JAMA/Archives journals. Expression of the cannabinoid 1 receptor (CB1R), the site of action of the main chemical ingredient of ma...ol (THC), the main psychoactive ingredient in marijuana, and the brains own cannabinoid chemical messengers." Dr. Lewis and his colleagues examined specimens of...
Cannabinoid in Medical Technology

Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief

HONOLULU, Jan. 28 /PRNewswire/ -- Researchers at Brigham and Women's Hospital found that patients taking cannabinoid medicines for pain may be getting "high," but these effects were unrelated to relief from their pain symptoms. Results of their study, one of the first to examine the addictive...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

...ntion and treatment of neuropathies and neurodegenerative disorders; a series of novel compounds for anxiety and depression; and a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. More infor...

Pharmos Issues Business Update on Dextofisopam Trial and Financing

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009

...ent Jan. 29 from 3:30-5 PM and Jan. 30 from 9-10 AM Calcium Channel Blockers Compared for Neuropathic Pain, Poster 181 Addictive Qualities of cannabinoid Medication, Poster 193 Tramadol Outcomes, Poster 197 Safety, Tolerability and Effectiveness of Duloxetine for Fibromyalgia, Poster 204 ...

Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

...advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its pipeline of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. More inform...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

...advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its pipeline of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and obesity. More informati...

CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)

...ver current agents for depression and are expected to have a good safety profile. The company is also developing its preclinical pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma and obesity. More information about CeNeRx BioPharma can be found at http://www.cenerx.com . Contac...
Cannabinoid in Medical Definition

Depolarization-induced suppression of inhibition

...to the demonstration that DSI was dependent on the cannabinoid CB1 receptor function, there was no way of produ...l three demonstrated heavy involvement of the CB1 cannabinoid receptor in DSI, suggesting that the endocannabi...re the brain's mediators of DSI. They showed that cannabinoid receptor agonists, drugs that mimic the actions o...
Cannabinoid in Medical Dictionary

Gliomas

...ades that reflect the degree of malignancy. ... Cannabinoids as a potential new drug therapy for the treatment of gliomas . ... Expression of cannabinoid receptors and neurotrophins in human gliomas . ... Find out how malignant gliomas are graded and how the grade affects treatment and prognosi...
Cannabinoid in Biological News

Scripps research team defines new painkilling chemical pathway

...ills pain by activating a set of proteins known as cannabinoid receptors, which can also regulate appetite, infla...ylglycerol (2-AG). These natural components of the cannabinoid system remain the focus of intense efforts to deve...but also induced other effects associated with the cannabinoid receptors, namely hypothermia and decreased moveme...

LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's

...ving COX-2 inhibitors has led to their recent withdrawal from the market and limits on their usages. Our research has shown that the use of endogenous cannabinoid 2-AG may avoid such side effects. Therefore, elevation of endogenous 2-AG levels by facilitating its production, inhibiting its decomposition, or dire...

Medicines derived from cannabis: a review of adverse events

...r cannibinoids, are available for medical purposes in Canada. As the use of cannabinoid medications increases, so do concerns about their potential to cause "adver...was based on the adverse events reported in 31 separate clinical studies of cannabinoid medications conducted between 1966 and 2007. Adverse events were categorize...

Study finds possible connection between marijuana abuse and stroke or heart attacks

... to impaired learning and memory. The active chemical in MJ called delta-9-tetrahyrdocannabinol (THC) is believed to exert these effects by binding to cannabinoid (CB) receptors located on several cell types in various organs. Scientists have found CB receptors in many organs including the brain, heart, liver, ...

Opium and marijuana research go underground

... research will identify novel genes for use in the metabolic engineering of opium poppy to accumulate high-value pharmaceutical alkaloids and to block cannabinoid production in cannabis. The latter will allow for a safe, legal, made-in-Canada cannabis crop that will have virtually none of the mind-altering chemi...

The endocannabinoids: Functional roles and therapeutic opportunities

...ell known marijuana effects. It was assumed that a cannabinoid receptor is not formed for the sake of a plant con...utative 'signaling' constituents together with the cannabinoid receptors are part of a new biochemical system in ...r after TBI. The endocannabinoids act via specific cannabinoid receptors, of which the CB1 receptors are most abu...

'Conversation stoppers' fight deadly bacterial infections

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Nanotechnology propels advances in regenerative medicine research

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Brown seaweed contains promising fat fighter, weight reducer

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Study shows enzyme builds neurotransmitters via newly discovered pathway

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...
Cannabinoid in Biological Technology

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

--By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds-- RESEARCH TRIANGLE PARK, N.C., April 1 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases o...

Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products

PALM SPRINGS, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset th...

Pharmos Corporation Reports 2008 Fourth Quarter Results

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

CeNeRx BioPharma Completes $15 Million Series B Financing

...Novel Antidepressant Tyrima(TM) and Advancement of cannabinoid Compounds - RESEARCH TRIANGLE PARK, N.C., Oct. 1...DD), to further characterize its novel preclinical cannabinoid pipeline and potentially to acquire additional dev...mpany is also developing its pipeline of selective cannabinoid compounds that have recently completed successful ...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

...NP marketing approval: lacosamide (Schwarz Pharma), milnacipran (Forest Laboratories/Cypress Bioscience), transdermal capsaicin (NeurogesX) and a dual cannabinoid receptor agonist (GW/Bayer), and fentanyl buccal (Cephalon). Eighteen drugs are in Phase III development in the US including two GABA receptor agonist...

Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

...patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation Reports 2008 First Quarter Results

...patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference

...nt for pain in patients with knee osteoarthritis. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation Reports 2007 Third Quarter Results

...nt for pain in patients with knee osteoarthritis. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...
Other Tags
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required ... select brands and items qualify for free standard shipping for customers regardless of the ...
(Date:8/29/2015)... , ... August 29, 2015 , ... The popular television ... Earl Jones, recently announced that it will be devoting an entire short segment to ... millions of people around the globe on a daily basis, but recent advancements in ...
(Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
Other Contents